About Exact Sciences
Exact Sciences is a leading molecular diagnostics company dedicated to eradicating cancer through prevention, early detection, and personalized treatment guidance. Founded in 1995 and headquartered in Madison, Wisconsin, the company has grown to serve over 120 countries with more than 6,500 employees globally. Exact Sciences develops and commercializes innovative cancer tests that explore hereditary risks, screen for cancer's presence, and examine the unique genomic alterations of an individual's cancer to help guide treatment decisions. The company's portfolio includes the widely-adopted Cologuard colorectal cancer screening test, the Oncotype DX suite of genomic tests for breast and colon cancer treatment guidance, and newer innovations like the Cancerguard multi-cancer early detection test. With nine research and development centers and state-of-the-art laboratories, Exact Sciences combines rigorous research, deep clinical expertise, and proven accuracy to deliver life-changing diagnostic solutions. The company has tested over 4 million people in 2023 alone and maintains strong collaborations with leading medical institutions, advocacy partners, and policymakers. Exact Sciences went public in February 2001 and has been certified as a Great Place to Work for seven consecutive years, reflecting its commitment to innovation, integrity, quality, teamwork, and accountability in the fight against cancer.
Mission & Story
Mission
We're united by a shared purpose: helping people live fuller lives through better health. We're committed to answering questions, solving problems, and making a lasting, positive impact on people's lives.
Clinical Focus
Medical conditions and clinical areas addressed by Exact Sciences.
Who It Serves
Milestones & Awards
Recent Milestones
Launch of three innovative cancer tests in 2025; Publication of BLUE-C study results in 2024; OncoExTra cancer therapy selection test launch in 2023; PreventionGenetics acquisition in 2022
Awards & Recognition
Certified Great Place to Work for 7 consecutive years
Key Partnerships
Social & Media
Latest Updates
Shedding light on cancer decisionsJune 4, 2026
1mo ago
Right Test, Right Time
2mo ago
Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026March 17, 2026
4mo ago
Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive YearMarch 4, 2026
4mo ago
Exact Sciences Announces Record Fourth Quarter and Full Year 2025 ResultsFebruary 13, 2026
5mo ago
Company Details
- Founded
- 1995
- Headquarters
- Madison, WI, USA
- Employees
- 5001-10000
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.